Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Recruiting Observational

Complex Arrhythmia Registry

NCT07024927 · tracked via the Priya Life Science China tracker
Phase
Observational
Started
2025-10-21
Last updated
2026-06-04

Condition(s) studied

Atrial Fibrillation (AF)Ventricular Tachycardia (VT)

Investigational drug(s) / intervention(s)

AF ablationVT ablation

AF ablation: Catheter ablation will be performed under general anesthesia or local anesthesia. Pulmonary vein isolation (PVI) was performed in all patients. Beyond this mandatory step, the specific ablation strategy/protocol and ablation parameters/settings will be determined at the discretion of the operating physicians at each participating center.

VT ablation: For patients with hemodynamically stable VT, comprehensive chamber mapping (including activation mapping, substrate mapping, and entrainment mapping) is recommended. This aims to elucidate the VT activation sequence and identify the critical isthmus. Precise ablation targeting the isthmus should be performed to terminate the VT. For patients with hemodynamically unstable VT, substrate mapping during sinus rhythm can be performed first. This includes identification of low-voltage zones and abnormal electrograms (e.g., late potentials, local abnormal ventricular activities - LAVAs). Targeted substrate modification ablation should then be conducted based on the mapping findings. For all patients, complete substrate mapping is recommended after VT termination.

Study summary

This is a prospective, non-randomized, multicenter observational registry study designed to systematically evaluate the long-term efficacy and safety of catheter ablation for treating atrial fibrillation (AF) and ventricular tachycardia (VT) in Chinese patients.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
1. Atrial Fibrillation (AF) Cohort: * Inclusion Criteria (Patients must meet ALL of the following criteria): 1. Age ≥ 18 years. 2. Diagnosed with atrial fibrillation (AF), including paroxysmal AF (PAF) and persistent AF (PsAF). 3. Scheduled to undergo first-time catheter ablation for AF. 4. Procedure to be performed using a 3D mapping system. 5. Provision of signed written informed consent for study participation and willingness and ability to comply with all protocol-required follow-up assessments. * Exclusion Criteria (Patients meeting ANY of the following criteria will be excluded): 1. Severe congenital heart disease (e.g., Tetralogy of Fallot, corrected transposition of the great arteries). 2. AF secondary to a clearly reversible cause (e.g., hyperthyroidism, post-operative state, acute alcohol intoxication). 3. Unstable angina pectoris or acute myocardial infarction (MI) within 30 days prior to enrollment/procedure. 4. Severe active infection (e.g., septic shock, sepsis). 5. Contraindications to anticoagulation therapy. 6. Current participation in another interventional clinical trial that may confound the results of this study. 7. Any other condition where, in the investigator's judgment, the patient is unsuitable for participation in this study. 2. Ventricular Tachycardia (VT) Cohort * Inclusion Criteria (Patients must meet ALL of the following criteria): 1. Age ≥ 18 years. 2. Diagnosed with ventricular tachycardia (VT) associated with underlying structural heart disease, including: 3. Ischemic heart disease (e.g., prior MI, coronary artery disease). 4. Non-ischemic cardiomyopathy (e.g., dilated cardiomyopathy (DCM), arrhythmogenic right ventricular cardiomyopathy (ARVC), hypertrophic cardiomyopathy (HCM)). 5. Scheduled to undergo first-time catheter ablation for VT. 6. Procedure to be performed using a 3D mapping system. 7. Provision of signed written informed consent for study participation and willingness and ability to comply with all protocol-required follow-up assessments. * Exclusion Criteria (Patients meeting ANY of the following criteria will be excluded): 1. VT due to a transient or reversible cause (e.g., acute myocardial ischemia, severe electrolyte imbalance). 2. Idiopathic ventricular tachycardia (VT occurring in the absence of structural heart disease). 3. Cardiac surgery within 60 days prior to the planned ablation procedure. 4. Severe coagulopathy (e.g., platelet count \< 50 x 10⁹/L, disseminated intravascular coagulation (DIC)). 5. Severe heart failure with left ventricular ejection fraction (LVEF) \< 20%. 6. Severe active infection (e.g., septic shock, sepsis). 7. Current participation in another interventional clinical trial that may confound the results of this study. 8. Any other condition where, in the investigator's judgment, the patient is unsuitable for participation in this study.

Primary outcome measure(s)

  • Freedom from any documented atrial arrhythmia in 12 months after the index ablation procedure — From the end of the 3-month blanking period post-ablation to the 12-month follow-up
  • Composite outcomes of ventricular tachycardia recurrence, cardiovascular hospitalization, or death during the 12-month follow-up — 12 months
    Recurrent ventricular tachycardia is defined as any appropriate implantable cardiac defibrillation therapy (shock or antitachycardia pacing) or documented sustained monomorphic ventricular tachycardia \>30 seconds. Cardiovascular rehospitalization is defined as a hospital admission after the randomly assigned procedure for heart failure, procedure-associated complications, or arrhythmic causes during the 12-month follow-up.

Trial sites (2)

FacilityCityRegionStatus
No. 2 Anzhen Rd, Chaoyang District, 100029 Beijing Beijing Municipality Recruiting
Beijing Anzhen Hospital, Capital Medical University Beijing China Not Yet Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07024927 on ClinicalTrials.gov ↗ ← All trials in China